Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Sputnik V

Sputnik V

Vaccine against COVID-19

Sputnik V is the world's first registered vaccine based on the well-studied human adenovirus vector platform.

The vaccine is named after the first Soviet space satellite.

The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors that cause the common cold and that humanity has faced for millennia.

"Vectors" are carriers that can deliver genetic material from another virus into a cell. In this, the genetic material of the adenovirus that causes the infection is removed and material coded for a protein from another virus, in this case the coronavirus spike, is inserted. This new element is safe for the body, but it helps the immune system respond and produce antibodies that protect against infection.

The adenovirus-based vector technology platform simplifies and accelerates the development of new vaccines by modifying the original carrier vector with genetic material from newly emerging viruses, which allows for the production of new vaccines in a short time. Such vaccines elicit a strong response from the human immune system.

Human adenoviruses are considered among the easiest to modify, which is why they have become very popular as vectors.

Phase 1 and 2 clinical trials of the vaccine were completed on August 1, 2020. The results of the third phase of clinical trials in Russia were published in the Lancet on February 2, 2021. Clinical trials of the third phase of Sputnik V are also successfully taking place in the United Arab Emirates, India, Venezuela and Belarus.

The effectiveness of the vaccine is 97.6% based on the analysis of data on the incidence of coronavirus among Russians vaccinated with both components of the drug in the period from December 5, 2020 to March 31, 2021.

Timeline

February 16, 2022
N. F. Gamaleya National Center of Epidemiology and Microbiology

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
By MARIA CHENG and MOGOMOTSI MAGOME
October 19, 2021
AP NEWS
JOHANNESBURG (AP) -- The South African drug regulator has rejected the Russian-made coronavirus vaccine Sputnik V, citing some safety concerns the manufacturer wasn't able to answer. The South African Health Products Regulatory Authority, or SAHPRA, said in a statement Tuesday that the request for Sputnik V to be authorized could "not be approved at this time," referring to past failed HIV vaccines that used a similar technology.
By The Associated Press
October 14, 2021
AP NEWS
BUDAPEST, Hungary -- Hungary recorded its highest daily number of new COVID-19 cases in five months Thursday amid a spike in coronavirus deaths and hospitalizations.Officials reported 1,141 new cases, the highest daily total since May 14.
Neetu Chandra Sharma
August 13, 2021
mint
The Russian Direct Investment Fund, and global pharmaceutical company Wockhardt Ltd have partnered to produce and supply Sputnik V and Sputnik Light covid-19 vaccines. The agreement was reached under the aegis of Enso Healthcare, RDIF's coordination partner for sourcing Sputnik V vaccines in India.
Sohini Das
August 13, 2021
@bsindia
This is twice the amount of doses Serum Institute of will make of the Russian shot, will take total Sputnik V capacity in India to 1.7 bn doses a year
Livemint
August 13, 2021
mint
Wockhardt enters into an agreement to manufacture and supply of the Sputnik V/Sputnik Light vaccine against Covid-19
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.